EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Effectiveness of SGLT-2 Inhibitors vs GLP-1 Receptor Agonists in Enhancing Kidney Function and Glycemic Control for Diabetes Mellitus Patients with CKD: A Narrative Review

Putu Ngurah Pradnya Wibawa, Ni Luh Putu Serly Ekayanti

Babali Nursing Research · 31.01.2026 · 7 (1) · 1-24

DOI: 10.37363/bnr.2026.71506 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Babali Nursing Research, online erschienen am 31.01.2026. Verfasst von Putu Ngurah Pradnya Wibawa und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introdution: Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) are highly interconnected, impacting global health. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) offer promising benefits for glycemic control, cardiovascular health, and kidney protection. This review compares their effectiveness in enhancing kidney function and glycemic control for T2DM patients with CKD.

Methods

A narrative review was conducted using the PICO framework, searching the PubMed database and online search (ScienceDirect and Google Scholar) for English-language observational research articles published between 2020 and 2025. Articles focused on SGLT2i and GLP-1RA therapies in T2DM patients with CKD, assessing kidney function and glycemic control. Fifteen articles were selected from an initial 706. The keyword use is “comparing” AND “effectiveness” AND “SGLT-2 inhibitor” AND “GLP-1 RA” AND “kidney function” AND “glycemic control” AND “T2DM” AND “CKD” AND “patients”.

Results

SGLT2 inhibitors consistently demonstrated strong renal protective effects, including slower eGFR decline and reduced kidney failure progression. GLP-1RAs excelled in glycemic control, weight management, and cardiovascular event reduction. While SGLT2i generally appeared superior for direct renal protection, some studies suggested comparable renal outcomes. Real-world data largely supported these findings, enhancing clinical applicability.

Conclusion

SGLT2 inhibitors are recommended for T2DM patients with CKD, especially those at higher renal risk. GLP-1RAs are valuable for glycemic control, weight, and cardiovascular benefits. Their complementary mechanisms suggest potential for additive benefits in combination therapy, necessitating further research to optimize patient outcomes.

Zitieren

APA

Wibawa, P. N. P., & Ekayanti, N. L. P. S. (2026). The Effectiveness of SGLT-2 Inhibitors vs GLP-1 Receptor Agonists in Enhancing Kidney Function and Glycemic Control for Diabetes Mellitus Patients with CKD: A Narrative Review. Babali Nursing Research, 7(1), 1-24. https://doi.org/10.37363/bnr.2026.71506

Vancouver

Wibawa PNP, Ekayanti NLPS. The Effectiveness of SGLT-2 Inhibitors vs GLP-1 Receptor Agonists in Enhancing Kidney Function and Glycemic Control for Diabetes Mellitus Patients with CKD: A Narrative Review. Babali Nursing Research. 2026;7(1):1-24. doi:10.37363/bnr.2026.71506

BibTeX
@article{Wibawa2026,
  author = {Wibawa, Putu Ngurah Pradnya and Ekayanti, Ni Luh Putu Serly},
  title = {The Effectiveness of SGLT-2 Inhibitors vs GLP-1 Receptor Agonists in Enhancing Kidney Function and Glycemic Control for Diabetes Mellitus Patients with CKD: A Narrative Review},
  journal = {Babali Nursing Research},
  year = {2026},
  volume = {7},
  number = {1},
  pages = {1--24},
  doi = {10.37363/bnr.2026.71506}
}
Kostenlos starten →